Repare Therapeutics introduces two initiatives set to commence clinical testing by 2024: oral PLK4 inhibitor RP-1664, and oral Polθ inhibitor RP-3467.

COX-2 inhibitors aid in the release of prostaglandins, which are synthesized from arachidonic acid. Prostaglandins play a key role in inflammatory responses.

Open reading frame (ORF), in the context of genomics, refers to a section of a DNA sequence that lacks a stop codon and potentially codes for a protein.

This article summarized the latest R&D progress of Umeclidinium Bromide, the Mechanism of Action for Umeclidinium Bromide, and the drug target R&D trends for Umeclidinium Bromide.

Alvotech, a global biotech firm specializing in biosimilar drugs, and Canada's JAMP Pharma have announced Health Canada's approval for AVT04, a Stelara® biosimilar. It will be marketed as Jamteki™.

The 2023 SITC Congress kicked off with a groundbreaking report on the latest clinical results of ENB-003, establishing a solid foundation for future research.

This article aims to instruct you on how to swiftly locate related sequences via a simple one-click method, using the target name.

This article summarized the latest R&D progress of Triptolide, the Mechanism of Action for Triptolide, and the drug target R&D trends for Triptolide.

Kyverna Therapeutics reveals FDA approval for Phase 2 study of KYV-101, a complete human CD19 CAR T-Cell treatment for Myasthenia Gravis.

On Oct 31, 2023, the latest clinical data of MDNA11 monotherapy in a phase 1/2 study on advanced solid tumors was reported at SITC Congress, showing potential efficacy for future research.

Latest news on PACIFIC-2 Phase III study of Imfinzi given along with platinum-based chemo and radiotherapy for Stage III non-small cell lung cancer that can't be surgically removed.

This article summarized the latest R&D progress of Voglibose, the Mechanism of Action for Voglibose, and the drug target R&D trends for Voglibose.